Our History


Medexus is born.

2000Medexus History timeline arrow
timeline arrow2001

Medexus receives Health Canada approval for Prosorba Column (Apheresis) for treatment of Rheumatoid Arthritis.

Medexus licenses the Magic Bullet bisocodyl suppository, indicated for bowel care.

2003Magic Bullet timeline arrow
timeline arrow2005

Health Canada approval and commercialization of Calcia® Calcium. Indicated to help maintain healthy bones.The number 1 selling calcium/vitamin D supplement in the world.

Medexus licenses Hyalgan (Hyaluronic Acid). Indicated for Osteoarthritis of the knee (Viscosupplementation).

2005Hyalgan timeline arrow
timeline arrow2006

Medexus licenses Oral Methotrexate 10mg, indicated for Rheumatoid Arthritis.

Health Canada approval and launch of Metoject® 10mg/ml (prefilled syringes of methotrexate), indicated for Rheumatoid rthritis, Psoriasis/Psoriatic Arthritis. Metoject® offers safety, efficacy and convenience over vials and manually compounded syringes.

2008Metoject 10mg timeline arrow
timeline arrow2008

" This 6‐month prospective, randomized, controlled trial is the first to examine oral versus SC administration of MTX. We found that SC administration was significantly more effective than oral administration of the same MTX dosage "

Health Canada approval and commercialization of Tricovel® indicated for telogen effluvium (short term hair loss due to stress medications hormones) Tricovel® is the number 1 selling product in Europe.

2014Tricovel timeline arrow
timeline arrow2014

CRA partner.

ORA partner

2014ORA partner timeline arrow
timeline arrow2014

AMRQ partner

OBRI partner

2015Timeline Photo timeline arrow
timeline arrow2015

CATCH partner.

Health Canada approval and commercialization of Oralvisc® Metabolic for joint pain in osteoarthritis. Oralvisc® is clinically proven to reduce leptin, reduce joint pain and improve joint function.

2015Oralvisc timeline arrow
timeline arrow2016

Health Canada approval and Launch of Metoject® Subcutaneous 50mg/ml (prefilled syringes of methotrexate). The first and only parenteral methotrexate approved by Health Canada for subcutaneous injection.

OPA Medexus sponsors and takes part in the Ontario Pharmacist Association Meeting.

2017OPA Sponser timeline arrow
timeline arrow2017

CPA Medexus sponsors and takes part in the Canadian Pharmacist Association Meeting.

Triamcinolone Hexacetonide (TH) Injectable Suspension is a synthetic corticosteroid indicated for intraarticular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases.

2017Triamcinolone Hexacetonide timeline arrow
timeline arrow2018

Health Canada approval and commercialization of Ironone®.

Health Canada approval and commercialization ofMulti-Gyn®.

2018Ironone timeline arrow